Can fatigue be improved in patients with Ehlers-Danlos Syndrome (EDS) with a genetic component?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Managing Fatigue in Ehlers-Danlos Syndrome with Genetic Component

Fatigue in Ehlers-Danlos Syndrome (EDS) can be significantly improved through a structured approach focusing on tailored physical activity, psychoeducational interventions, and addressing underlying factors, even when there is a genetic component to the condition.

Understanding Fatigue in EDS

  • Fatigue is a frequent and clinically significant problem affecting more than three-quarters of EDS patients 1
  • Fatigue in EDS is multifactorial, involving sleep disturbances, concentration problems, social functioning issues, self-efficacy concerns, and pain severity 1
  • Patients with EDS often experience worsening symptoms over time, with fatigue being universal and often resulting from or contributing to pain and disordered sleep 2

Evidence-Based Management Strategies

Physical Activity Interventions

  • Tailored physical activity programs should be offered to EDS patients with fatigue as part of their clinical care 3
  • Physical activity should be structured and individualized based on the patient's specific needs, capabilities, and disease manifestations 3
  • Long-term physical activity as a lifestyle change should be encouraged rather than short-term interventions 3
  • Physical therapy with attention to methods preventing deconditioning is essential for comprehensive fatigue management 4

Psychoeducational Interventions

  • Structured psychoeducational interventions that go beyond information provision should be offered to explore thoughts, feelings, and behaviors related to fatigue 3
  • These interventions should be periodically reassessed and not restricted based on previous participation 3
  • Cognitive behavioral approaches may be particularly helpful for addressing fatigue-related issues in EDS 1, 4

Medical Evaluation and Treatment

  • Evaluation for underlying causes of fatigue should include assessment for:

    • Sleep disorders, which are common contributors to fatigue in EDS 4
    • Autonomic dysfunction, particularly POTS (Postural Orthostatic Tachycardia Syndrome) 5, 6
    • Gastrointestinal issues, which affect up to 98% of hypermobile EDS patients 6
    • Nutritional deficiencies that may contribute to fatigue 4
  • For patients with suspected autonomic dysfunction:

    • Assess for orthostatic tachycardia using postural vital signs 5
    • Consider referral for autonomic function testing including tilt table testing 5

Multidisciplinary Approach

  • A multidisciplinary team approach is recommended, involving:
    • Rheumatologists for joint hypermobility management 6
    • Cardiologists for evaluation of cardiovascular autonomic dysfunction 6, 4
    • Gastroenterologists for assessment of GI manifestations 5, 6
    • Sleep specialists for addressing sleep disturbances 4

Self-Management Strategies

  • Patients often develop their own strategies to adapt to their limitations when conventional medicine is unsuccessful 2
  • Complementary interventions may be beneficial as part of a comprehensive approach 2
  • Self-care strategies should be guided by knowledgeable medical providers 2

Important Considerations and Pitfalls

  • Diagnostic catheter angiography carries increased risks in patients with collagen vascular diseases; non-invasive imaging should be used whenever possible 7
  • For patients with vascular EDS (Type IV), special caution is needed with any invasive procedures due to risk of arterial rupture 7, 6
  • Opioid medications should be avoided for chronic pain management in EDS patients 5
  • Fatigue management should be needs-based and not restricted by previous treatment attempts, as fatigue factors can change over time 3

Monitoring and Follow-up

  • Regular assessment of fatigue severity, impact, and coping strategies should be part of usual care 3
  • Shared decision-making between patients and healthcare providers is essential for effective fatigue management 3
  • Ongoing medical evaluation for new problems and review of new evidence about proposed treatments is necessary 4

Related Questions

What is causing the excessive fatigue in a 51-year-old male with tethered cord syndrome, adhesive arachnoiditis, chronic osteomyelitis, intractable pain, and prolonged (>25 hours/day) sleep?
How should a patient with hypermobile Ehlers-Danlos syndrome (hEDS) and chronic fatigue, presenting with persistent tachycardia, be evaluated and managed?
What symptoms would suggest a connective tissue disease in a patient with Attention Deficit Hyperactivity Disorder (ADHD)?
What is the most likely cause of my pain flare-ups with rain and humidity given my medical conditions, including cervical kyphosis, scoliosis, lordosis, congenital spinal canal narrowing, and hypermobile Ehlers-Danlos Syndrome (EDS)?
Can I still experience post-exertional malaise with hypermobile Ehlers-Danlos Syndrome (hEDS), sleep apnea, autonomic dysfunction, hyperglycemia, and potential hypothyroidism or Hashimoto's Thyroiditis?
What are the recommended treatments for nightmares, including medication options such as prazosin (Prazosin) and selective serotonin reuptake inhibitors (SSRIs)?
What is the maximum recommended dose of carvedilol (beta-blocker) for heart failure and hypertension?
What antipsychotics are approved as monotherapy for bipolar disorder?
What are the treatment options for conjunctivitis?
What is the recommended approach for switching from lisinopril (Angiotensin-Converting Enzyme Inhibitor) to losartan (Angiotensin II Receptor Blocker) in a patient with a history of angioedema?
Is albuterol (short-acting beta agonist) necessary for asthma patients with well-controlled inhaler therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.